RxDoctor Payments Data

Erica Herc

Infectious Disease · Detroit, MINPI 1891058418

Payments from drug & device makers

What this record shows

3 manufacturers reported payments, led by Astellas Pharma US Inc at 55.3% of the total.

$573in general payments, 2019–2025

Across 6 payments — averaging $95.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$317
  • Merck$144
  • Shionogi Inc$111
$318,140in research payments, 2019–2025

Across 31 payments — averaging $10,263 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Janssen Research & Development, LLC$188K
  • Mannkind Corporation$80K
  • Modernatx, Inc.$51K

What the payments were for

  • Food & beverage$25645%
  • Education$31755%

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Astellas Pharma US Inc4$317
Merck1$144
Shionogi Inc1$111

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$573 in reported general payments places this provider in the 70th percentile of 257 infectious disease providers in Michigan.

See all infectious disease providers in Michigan

Medicare billing

Part B allowed, 2024
$41,208
Medicare patients
133
Services billed
326

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other infectious disease in Detroit

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →